Open Orphan


Open Orphan spin-out Poolbeg upbeat despite losses – 3 March 2022

  • The London-listed firm, which counts biochemistry professor Luke O’Neill among its advisory board members, announced a £2.3m (€2.78m) loss in 2021, including a one-off cost from establishing the group last summer.
  • Poolbeg is targeting the growing infectious disease market, which is expected to be worth $250bn by 2025, and is due to start human trials for a severe flu treatment in June.

Open Orphan firm signs £5m contract to trial new flu drug – 21 Dec 2021

Open Orphan subsidiary wins $13.4m contract with US biotech company – 10 Dec 2021

Open Orphan subsidiary secures £8.1m contract for asthma study – 24 Aug 2021


Open Orphan spin-out Poolbeg Pharma to list on London market – 17 June 2021

Demerger Update on Poolbeg Pharma – 17 June 2021

Open Orphan subsidiary wins €7.5m contract to run study – 26 March 2021

Open Orphan (LON:ORPH) Presenting at the Proactive One2One Virtual Forum – 11 March 2021

Open Orphan’s Venn business wins contract to support clinical trial – 9 March 2021

What do we know about the UK trial to infect people with Covid-19? – 17 Feb 2021

Open Orphan jumps as COVID-19 study receives ethics approval – 17 Feb 2021

World’s first Covid-19 study where people are infected with virus to begin in London – Government funding of around £33m was given to the human challenge trial. – Shares in Open Ophan, which manages medical trials for a range of pharma companies and universities, are up more than seven per cent on the news. -17 Feb 2021

What happened the Creeslough man who left school early? – 13 Feb 2021

Medical trial firm converts East End hotel as Covid19 nasal vaccine study ramps up – 3 Feb 2021

Little-known Irish pharma firm Open Orphan is among best performing on stock exchange on Covid-19 work – 19 Nov 2020

Business Person of the Month October 2020: Cathal Friel, executive chairman of Open Orphan – 2 Nov 2020

UK taps Open Orphan to explore vaccine trials that infect volunteers with coronavirus – The characterization study is expected to be complete in 2021 and is still subject to ethical and regulatory approval. Sponsored by Imperial College in the U.K., the study will be conducted by Open Orphan’s hVivo unit at a London-based research site. – 20 Oct 2020

Contract Signed with UK Government – 20 Oct 2020

Cathal Friel, Executive Chair, Open Orphan speaking at London South East’s September Webinar – Sickness & Disease the number 1 investment! –  1 Oct 2020

Open Orphan wins new £4.3m challenge study deal with top vaccine company – 28 Sept 2020

Open Orphan to merge with UK-based Hvivo in £30m tie-up – 9 Dec 2019

‘Curiosity has helped me stand out – I’ve worked since age 16 and I’ve had seven careers’ – 6 Aug 2019

Business Leaders – Cathal Martin Friel

Are you thinking something is not quite right?